A comparison of therapy continuation rates of different hormone replacement agents: A 9-month retrospective, longitudinal analysis of pharmacy claims among new users

Menopause

Volumn 10, Issue 1, 2003, Pages 37-44

  Simon, James A ^a   Wysocki, Susan ^a   Brandman, Jane ^a   Axelsen, Kirsten ^a  

^a NONE

Author keywords

Adherence; Claims analysis; Continuation rates; Hormone replacement therapy; Menopause; Patient compliance

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FEMHRT; UNCLASSIFIED DRUG; ETHINYLESTRADIOL PLUS NORGESTREL;

ADULT; AGE; ARTICLE; COMPARATIVE STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENOPAUSE; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACY; PHYSICIAN; POSTMENOPAUSE; PRESCRIPTION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; CLINICAL PRACTICE; COHORT ANALYSIS; ECONOMICS; ESTROGEN THERAPY; HEALTH INSURANCE; INSURANCE; MALE; MIDDLE AGED; RISK; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0037507396     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200310010-00007     Document Type: Article

References (22)

1. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-229.
2. Björn I, Bäckström T. Drug related negative side effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
3. Vihtämaki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 1999;33:99-105.
4. Limouzin-Lamothe M-A. What women want from hormone replacement therapy: results of an international survey. Eur J Obstet Gynecol Reprod Biol 1996;64(Suppl 1):S21-S24.
5. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-512.
6. Bond M, Bywaters P. Towards understanding women's decisions to cease HRT. J Adv Nurs 1999;29:852-858.
7. The ESHRE Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. Hum Reprod 2000;15:1865-1871.
8. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health 1997;6:219-2126.
9. Ettinger B, Li D-K, Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause 1996;3:185-189.
10. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol 2000;96:366-372.
11. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000;182:270-276.
12. Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001;8:321-327.
13. Rozenberg S, Vandromme J, Kroll M, Pastijn A, Liebens F. Compliance to hormone replacement therapy. Int J Fertil Menopausal Stud 1995;40(Suppl 1):23-32.
14. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97:97-100.
15. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care 1999;5:779-785.
16. Gass M. HRT adherence issues. Menopausal Medicine 2001;1:6-8.
17. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159-171.
18. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42-45.
19. Barrett-Connor E, Espeland MA, Greendale GA, et al. Postmenopausal hormone use following a 3-year randomized clinical trial. J Womens Health Gend Based Med 2000;9:633-643.
20. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
21. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
22. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.